Literature DB >> 34861035

Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma.

AnnaLynn M Williams1, Sedigheh Mirzaei Salehabadi2, Mengqi Xing2, Nicholas S Phillips1, Matthew J Ehrhardt1,3, Rebecca Howell4, Yutaka Yasui1, Kevin C Oeffinger5, Todd Gibson6, Eric J Chow7, Wendy Leisenring7, Deokumar Srivastava2, Melissa M Hudson1,3, Leslie L Robison1, Gregory T Armstrong1, Kevin R Krull1,8.   

Abstract

Long-term survivors of childhood Hodgkin lymphoma (HL) experience a high burden of chronic health morbidities. Correlates of neurocognitive and psychosocial morbidity have not been well established. A total of 1760 survivors of HL (mean ± SD age, 37.5 ± 6.0 years; time since diagnosis, 23.6 ± 4.7 years; 52.1% female) and 3180 siblings (mean age, 33.2 ± 8.5 years; 54.5% female) completed cross-sectional surveys assessing neurocognitive function, emotional distress, quality of life, social attainment, smoking, and physical activity. Treatment exposures were abstracted from medical records. Chronic health conditions were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.3 (1 = mild, 2 = moderate, 3 = severe/disabling, and 4 = life-threatening). Multivariable analyses, adjusted for age, sex, and race, estimated relative risk (RR) of impairment in survivors vs siblings and, among survivors, risk of impairment associated with demographic, clinical, treatment, and grade 2 or higher chronic health conditions. Compared with siblings, survivors had significantly higher risk (all, P < .05) of neurocognitive impairment (eg, memory, 8.1% vs 5.7%), anxiety (7.0% vs 5.4%), depression (9.1% vs 7%), unemployment (9.6% vs 4.4%), and impaired physical/mental quality of life (eg, physical function, 11.2% vs 3.0%). Smoking was associated with a higher risk of impairment in task efficiency (RR, 1.56; 95% confidence interval [CI], 1.02-2.39), emotional regulation (RR, 1.84; 95% CI, 1.35-2.49), anxiety (RR, 2.43; 95% CI, 1.51-3.93), and depression (RR, 2.73; 95% CI, 1.85-4.04). Meeting the exercise guidelines of the Centers for Disease Control and Prevention was associated with a lower risk of impairment in task efficiency (RR, 0.70; 95% CI, 0.52-0.95), organization (RR, 0.60; 95% CI, 0.45-0.80), depression (RR, 0.66; 95% CI, 0.48-0.92), and multiple quality of life domains. Cardiovascular and neurologic conditions were associated with impairment in nearly all domains. Survivors of HL are at elevated risk for neurocognitive and psychosocial impairment, and risk is associated with modifiable factors that provide targets for interventions to improve long-term functional outcomes.

Entities:  

Mesh:

Year:  2022        PMID: 34861035      PMCID: PMC9121843          DOI: 10.1182/blood.2021013167

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  46 in total

1.  Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Sharon M Castellino; Ann M Geiger; Ann C Mertens; Wendy M Leisenring; Janet A Tooze; Pam Goodman; Marilyn Stovall; Leslie L Robison; Melissa M Hudson
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

2.  Reliability and validity of the Childhood Cancer Survivor Study Neurocognitive Questionnaire.

Authors:  Kevin R Krull; Gerard Gioia; Kirsten K Ness; Leah Ellenberg; Christopher Recklitis; Wendy Leisenring; Sujuan Huang; Marilyn Stovall; Leslie L Robison; Lonnie Zeltzer
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

3.  Age-dependent changes in health status in the Childhood Cancer Survivor cohort.

Authors:  Melissa M Hudson; Kevin C Oeffinger; Kendra Jones; Tara M Brinkman; Kevin R Krull; Daniel A Mulrooney; Ann Mertens; Sharon M Castellino; Jacqueline Casillas; James G Gurney; Paul C Nathan; Wendy Leisenring; Leslie L Robison; Kirsten K Ness
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

4.  Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Authors:  Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly
Journal:  Lancet Oncol       Date:  2018-08-16       Impact factor: 41.316

Review 5.  Adverse psychological effects of corticosteroids in children and adolescents.

Authors:  F A Stuart; T Y Segal; S Keady
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

Review 6.  Social outcomes in the Childhood Cancer Survivor Study cohort.

Authors:  James G Gurney; Kevin R Krull; Nina Kadan-Lottick; H Stacy Nicholson; Paul C Nathan; Brad Zebrack; Jean M Tersak; Kirsten K Ness
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Long-Term Neurocognitive and Psychosocial Outcomes After Acute Myeloid Leukemia: A Childhood Cancer Survivor Study Report.

Authors:  Kristen J Stefanski; Julia S Anixt; Pamela Goodman; Katherine Bowers; Wendy Leisenring; K Scott Baker; Karen Burns; Rebecca Howell; Stella Davies; Leslie L Robison; Gregory T Armstrong; Kevin R Krull; Christopher Recklitis
Journal:  J Natl Cancer Inst       Date:  2021-04-06       Impact factor: 13.506

8.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

9.  Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Authors:  Monika L Metzger; Michael P Link; Amy L Billett; Jamie Flerlage; John T Lucas; Belinda N Mandrell; Matthew J Ehrhardt; Nickhill Bhakta; Torunn I Yock; Alison M Friedmann; Pedro de Alarcon; Sandra Luna-Fineman; Eric Larsen; Sue C Kaste; Barry Shulkin; Zhaohua Lu; Chen Li; Susan M Hiniker; Sarah S Donaldson; Melissa M Hudson; Matthew J Krasin
Journal:  J Clin Oncol       Date:  2021-04-07       Impact factor: 50.717

10.  Psychological outcomes in long-term survivors of childhood leukemia, Hodgkin's disease, and non-Hodgkin's lymphoma: a report from the Childhood Cancer Survivor Study.

Authors:  Brad J Zebrack; Lonnie K Zeltzer; John Whitton; Ann C Mertens; Lorrie Odom; Roger Berkow; Leslie L Robison
Journal:  Pediatrics       Date:  2002-07       Impact factor: 9.703

View more
  1 in total

1.  A (modifiable) way to better Hodgkin lymphoma survivorship?

Authors:  James R Cerhan
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.